Saman Khaled
Papers
1
Total Citations
38
H-Index
1
About
Saman Khaled is a pioneering researcher in precision oncology and radiogenomics, whose work bridges drug development and genomic biomarker discovery. Her key research areas include molecular targeted radiosensitizers, cancer cell line screening platforms, and the integration of genomic annotations to personalize radiotherapy. Khaled’s major contribution lies in demonstrating that large, annotated cancer cell line collections—traditionally used for short-term drug survival assays—can be adapted to identify associations between targeted radiosensitizers and specific genomic alterations. This approach has the potential to streamline the clinical translation of biomarkers for radiation therapy, offering a powerful tool for matching patients with the most effective treatments. Her seminal 2015 paper on this platform has garnered 38 citations, reflecting its influence in the field. Khaled’s work is notable for its methodological rigor and translational impact, providing a framework that could accelerate the discovery of radiosensitizers tailored to tumor genetics. For students and researchers, her research exemplifies how integrating genomics with drug screening can unlock new avenues in cancer therapy, making her a key figure in the evolving landscape of precision radiation oncology.
Research Focus
Key Achievements
Top Papers
- 1